Participated · Equity · Jul 2026

Plantopia leverages molecular farming to develop plant-based dairy proteins, with a flagship casein product intended to mimic the texture, structure, and melting behavior of traditional cheese. The company is transitioning from research and development toward commercial-scale production. Its technology is positioned as a sustainable alternative to conventional animal-based dairy ingredients. The recent US$9 million financing led by Schreiber Foods and Siddhi Capital is intended to support commercial production, regulatory expansion, and manufacturing capabilities. The company aims to enable high-performance plant-based dairy ingredients for the food industry. The article does not provide operating metrics such as revenue or user figures.

Participated · Equity · Jul 2026

Hemispheric developed Descartes, a 6-billion-parameter NeuroAI foundation model trained on a proprietary multimodal EEG and behavioral dataset of more than 250,000 hours from over 100,000 participants. Descartes is designed to translate brain electrical activity into objective measures that can detect disease earlier, distinguish disorder subtypes, and guide treatment selection. The company deploys a lightweight dry EEG headset worn for about 15 minutes while users interact with an app to capture brain activity without surgery or lengthy protocols. Hemispheric has built dedicated data-collection labs and model-training infrastructure and demonstrated its platform to the FDA's Center for Devices and Radiological Health while pursuing a broad regulatory strategy. Its initial clinical applications target conditions including PTSD, mTBI, depression, anxiety, schizophrenia, and Alzheimer’s disease. The company has a 112-person interdisciplinary team and announced a $52 million early-stage financing to accelerate deployment, grow its data network, and advance regulatory and commercial efforts.

Participated · Series A · Jun 2026

Bionyra is advancing a pipeline of next-generation mono- and multispecific antibodies engineered with half-life extension to target immune pathways in diseases with high unmet need. Lead programs include BYN-002, a TL1A monoclonal antibody in a fully enrolled Phase 1 in healthy subjects; BYN-003, a TL1A*IL-23p19 bispecific that entered Phase 1 in April; and BYN-001, an IL-25 monoclonal antibody in IND-stage for atopic dermatitis and type 2 inflammation. The company holds exclusive global rights to these assets outside Greater China through licenses from TrueLab Biopharmaceutical and NovaRock Biotherapeutics, and is progressing additional preclinical assets. Bionyra was co-founded and seed financed by Sofinnova Partners and is led by CEO Frédéric Marrache, a former Sanofi R&D executive with experience in immunology and inflammation. The company plans to use its Series A proceeds to advance clinical development and rapidly generate clinical validation in dermatology and inflammatory bowel disease.

Participated · Seed · Jun 2026

Shifters builds supervised autonomous ground robotic teams that enable operators to coordinate mission-configurable robots to enter, sense and operate in dangerous environments ahead of people. Its platform combines AI decision-making, mission orchestration and modular robotic systems designed with Modular Open Systems Approach (MOSA) principles, robust APIs and partner integration. The company has completed demonstrations of coordinated robotic entry and navigation capabilities with defense and security stakeholders. Reported use cases span defense and national security (reconnaissance, intelligence gathering, perimeter monitoring and high-risk mission preparation) as well as commercial applications like infrastructure inspections, agriculture, mining and search and rescue. Shifters is headquartered in Washington, D.C. and operates in the U.S., Middle East and Europe. Financially, the company has raised $10.2 million in this seed round, bringing total funding to $15 million to support AI development, manufacturing readiness and global expansion.

Participated · Equity · Apr 2026

Stark Power focuses on developing energy infrastructure and hyperscale data center campuses in the U.S., pursuing a “Power First” strategy that couples co-located power generation with digital infrastructure. The company recently acquired Sagebrush Infrastructure Partners, which is advancing a portfolio of five hyperscale data center campuses in the U.S. Midwest totaling approximately 5.6 GW. Stark Power plans to use proceeds from its latest equity raise primarily to fund complementary power generation assets across its data center portfolio. The firm is backed by institutional investors and increased institutional conviction with Migdal Insurance becoming a significant shareholder through the current financing. The company is headquartered in Tel Aviv and is accelerating development across its pipeline following the Sagebrush acquisition.